CureVac
Dr. Christoph Erbacher is a highly experienced professional in the field of scientific research and development, currently serving as Senior Manager for Early Process Development at CureVac AG since May 2018. Previously, Dr. Erbacher held various leadership roles at QIAGEN from August 1995 to July 2017, including Senior Director - Head of R&D Scientific Applications and Scientific Director. Dr. Erbacher's early career included a position as a scientific researcher at Ciba-Geigy in the field of analytical research and microfluidics. Educational qualifications include a Doctorate in Technical Chemistry from EPFL and a Diplom in Chemistry from the Karlsruhe Institute of Technology.
This person is not in any offices
CureVac
8 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.